Amgen Inc
AMGN- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000318154
In the last 90 days, Amgen Inc insiders filed 0 open-market purchases and 3 sales; 3,168 institutions reported holding it in 13F filings for Q2 2026, worth $161.7B in total; no superinvestor holds it.
Superinvestors holding AMGN, Q2 2026
No superinvestor reported holding AMGN in Q2 2026.
Moves by quarter
Superinvestors that opened, added to, trimmed or sold out of AMGN each quarter, comparing shares with the quarter before. A superinvestor that didn't file for a quarter isn't listed, and isn't counted as selling.
Q1 2026
0 superinvestors holding at quarter end
- Sold out
- ARK Invest
Q4 2025
1 superinvestor holding at quarter end
- Reduced
- ARK Invest (−4.0%)
Q3 2025
1 superinvestor holding at quarter end
- Reduced
- ARK Invest (−18.4%)
Q2 2025
1 superinvestor holding at quarter end
- Reduced
- ARK Invest (−1.9%)
Q1 2025
1 superinvestor holding at quarter end
- Reduced
- ARK Invest (−11.1%)
Q4 2024
1 superinvestor holding at quarter end
- Reduced
- ARK Invest (−13.4%)
Q3 2024
1 superinvestor holding at quarter end
- Added
- ARK Invest (+2.4%)
Q2 2024
1 superinvestor holding at quarter end
- Added
- ARK Invest (+44.8%)
Q1 2024
1 superinvestor holding at quarter end
- New
- ARK Invest
Q4 2023
0 superinvestors holding at quarter end
- Sold out
- Gates Foundation Trust, Maverick Capital
Q3 2023
2 superinvestors holding at quarter end
Q3 2021
0 superinvestors holding at quarter end
- Sold out
- Maverick Capital
Q2 2021
1 superinvestor holding at quarter end
- Added
- Maverick Capital (+1,432.1%)